79 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs
8-K
EX-1.1
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
, sales commission, customer incentive programs and other business arrangements. Any misconduct could also involve the improper use or misrepresentation
424B5
lo7md68b s2zb7t2iqvn
23 Jun 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
p5e 93zjhv
23 Jun 22
Other Events
4:04pm
424B5
gcnndzoc4 7ard78ssgx
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
k8qmz5b1e80wuhu0
1 Mar 22
Prospectus supplement for primary offering
5:12pm
8-K
EX-10.1
uieji9vr9u mi
12 Jan 22
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
8:04am
424B5
raneeb6kgtvu
6 Oct 21
Prospectus supplement for primary offering
5:05pm